|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 5,863,935: Novel Pyrrolo[2,3-d]pyrimidines and Their Therapeutic Applications
U.S. Patent 5,863,935, granted on January 26, 1999, to SmithKline Beecham Corporation, covers a class of novel pyrrolo[2,3-d]pyrimidine compounds. These compounds exhibit kinase inhibitory activity, particularly against Janus kinases (JAKs), and are claimed for the treatment of various inflammatory and autoimmune diseases. The patent’s scope encompasses the compounds themselves, pharmaceutical compositions containing them, and methods of treating disease by administering these compounds.
What is the core invention claimed in U.S. Patent 5,863,935?
The patent claims novel pyrrolo[2,3-d]pyrimidine compounds. These compounds are defined by a specific chemical structure with various substituents, allowing for a broad range of potential therapeutic agents. The core structure is characterized by a fused ring system comprising a pyrrole ring and a pyrimidine ring.
The patent specifies a general formula for these compounds, which includes:
- A core pyrrolo[2,3-d]pyrimidine moiety.
- Substituents at various positions on this core structure, denoted by R1, R2, R3, R4, and R5.
- Specific definitions for each of these substituents, which include alkyl groups, substituted alkyl groups, aryl groups, heteroaryl groups, and various functional groups like amino, hydroxyl, and halogen.
For example, the patent defines R1 as typically being hydrogen or an alkyl group, while R2 and R3 are specified to be within certain ranges or can be absent. R4 and R5 are particularly detailed, allowing for significant structural variation.
The patent provides numerous specific examples of claimed compounds, detailing their chemical names and, in some instances, structural representations. These examples illustrate the breadth of the chemical space covered by the patent.
What are the asserted therapeutic uses for these compounds?
The primary therapeutic application for the claimed pyrrolo[2,3-d]pyrimidine compounds is the treatment of diseases mediated by the aberrant activity of kinases, particularly Janus kinases (JAKs). JAKs are a family of intracellular tyrosine kinases that play a crucial role in signal transduction pathways for many cytokines and growth factors. Dysregulation of JAK signaling is implicated in a variety of inflammatory and autoimmune conditions.
The patent explicitly lists the following conditions for which the claimed compounds are asserted to be useful:
- Inflammatory diseases: This category includes a broad spectrum of conditions characterized by inflammation, such as arthritis, inflammatory bowel disease, and psoriasis.
- Autoimmune diseases: Diseases where the immune system mistakenly attacks the body's own tissues, including rheumatoid arthritis, systemic lupus erythematosus, and multiple sclerosis.
- Allergic conditions: Such as asthma and atopic dermatitis.
- Cancer: Specifically, hematological malignancies and solid tumors where aberrant kinase activity contributes to tumor growth and survival. The patent mentions treatment of myeloproliferative disorders.
- Organ transplant rejection: Conditions where the recipient's immune system attacks the transplanted organ.
The mechanism of action described is the inhibition of kinase activity, leading to the suppression of downstream signaling pathways that promote inflammation and cellular proliferation.
What is the scope of the claims, and what specific aspects are protected?
U.S. Patent 5,863,935 has multiple claims covering different aspects of the invention. The claims can be broadly categorized into:
Compound Claims
These are the most fundamental claims, defining the chemical structures that are protected.
- Claim 1: This is an independent claim that defines the general formula for the pyrrolo[2,3-d]pyrimidine compounds. It sets forth the core scaffold and the permissible variations through substituents R1 to R5. The broad definitions of these substituents create a wide scope for the claimed compounds.
- Claims 2-10: These are dependent claims that narrow the scope of Claim 1 by providing specific definitions for one or more of the substituents (R1-R5). For instance, a dependent claim might specify that R1 is a particular alkyl group or that R4 is a substituted aryl ring. This provides additional protection for specific, potentially more potent or selective, embodiments of the general formula.
Pharmaceutical Composition Claims
These claims protect the formulations that can be used to administer the claimed compounds to patients.
- Claim 11: This independent claim covers a pharmaceutical composition comprising a pharmaceutically acceptable carrier and an effective amount of a compound as defined in Claim 1. This means any formulation containing any of the claimed compounds is protected.
- Claims 12-13: Dependent claims may further specify the type of carrier or dosage form, although the core protection lies in the combination of a claimed compound with a carrier.
Method of Treatment Claims
These claims protect the use of the claimed compounds to treat specific diseases.
- Claim 14: This independent claim covers a method of treating a disease mediated by kinase activity, which comprises administering to a patient an effective amount of a compound as defined in Claim 1. This protects the therapeutic application of the compounds.
- Claims 15-19: These dependent claims specify the types of diseases that can be treated, aligning with the therapeutic uses discussed previously, such as inflammatory, autoimmune, allergic, and myeloproliferative diseases.
The overall scope is broad, covering not only the specific compounds exemplified but also a vast array of structurally related compounds defined by the general formula. The protection extends to the use of these compounds in treating a wide range of diseases mediated by kinase activity.
What is the current patent landscape for pyrrolo[2,3-d]pyrimidine kinase inhibitors?
The patent landscape for pyrrolo[2,3-d]pyrimidine kinase inhibitors is complex and competitive, with significant activity from both major pharmaceutical companies and smaller biotechnology firms. U.S. Patent 5,863,935 represents an early foundational patent in this area.
Several key trends and observations are relevant to understanding the landscape:
- Evolving Selectivity: Early patents, like 5,863,935, often covered broad classes of compounds with general kinase inhibitory activity. Subsequent patent filings have focused on developing compounds with improved selectivity for specific JAK isoforms (JAK1, JAK2, JAK3, TYK2) or other related kinases. This increased selectivity aims to improve efficacy and reduce off-target side effects.
- New Therapeutic Indications: While the initial focus was on inflammatory and autoimmune diseases, research has expanded to include other indications like fibrotic diseases, certain cancers, and viral infections, leading to new patent filings for these applications.
- Formulation and Delivery: Patents are also being filed for novel pharmaceutical formulations, delivery systems, and combination therapies involving pyrrolo[2,3-d]pyrimidine derivatives. This includes sustained-release formulations, topical applications, and combinations with other therapeutic agents.
- Generational Development: Major pharmaceutical companies often have multiple generations of patents covering their lead compounds and next-generation inhibitors. This strategy helps to extend market exclusivity and protect their R&D investments.
- Generic Competition: As foundational patents, such as 5,863,935, expire or approach expiration, the landscape becomes more susceptible to generic competition. However, later patents covering specific compounds, formulations, or uses may still provide ongoing market protection.
- Litigation: The high therapeutic and commercial value of kinase inhibitors frequently leads to patent litigation, involving challenges to patent validity, inventorship disputes, and allegations of infringement.
The patent landscape reflects ongoing innovation in the discovery of new chemical entities within the pyrrolo[2,3-d]pyrimidine scaffold, refinement of their therapeutic applications, and optimization of their delivery and manufacturing processes.
What are the key molecules and drugs that have emerged from this patent family or related scaffolds?
While U.S. Patent 5,863,935 covers a broad class of compounds, specific drugs that have emerged from this structural class are often the result of extensive research and development, leading to further patent filings for optimized compounds. The pyrrolo[2,3-d]pyrimidine scaffold has proven to be a highly productive area for kinase inhibitor discovery.
Notable examples of drugs based on or related to this scaffold include:
- Tofacitinib (Xeljanz®): Developed by Pfizer, tofacitinib is a JAK inhibitor approved for the treatment of rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and polyarticular course juvenile idiopathic arthritis. Its development represents a significant advancement in the therapeutic application of JAK inhibition. While tofacitinib itself may not be directly claimed in the broad scope of U.S. Patent 5,863,935, it is a prominent example of a drug based on the highly investigated pyrrolo[2,3-d]pyrimidine scaffold. Its structure is a pyrrolo[2,3-d]pyrimidine derivative with specific modifications.
- Ruxolitinib (Jakafi®/Jakavi®): Developed by Incyte and marketed by Novartis, ruxolitinib is a JAK1/JAK2 inhibitor approved for myelofibrosis and polycythemia vera. It was the first JAK inhibitor approved for these myeloproliferative neoplasms. Similar to tofacitinib, ruxolitinib is a pyrrolo[2,3-d]pyrimidine derivative.
- Baricitinib (Olumiant®): Developed by Eli Lilly, baricitinib is a JAK1/JAK2 inhibitor approved for rheumatoid arthritis and alopecia areata. It is another significant entrant in the JAK inhibitor market based on the pyrrolo[2,3-d]pyrimidine structure.
These drugs, while representing specific optimized embodiments of the broader chemical space explored by early patents like 5,863,935, are protected by their own subsequent and more specific patent families covering their exact structures, formulations, and uses. The success of these drugs validates the therapeutic potential of the pyrrolo[2,3-d]pyrimidine scaffold, which was initially defined by patents such as 5,863,935. The research initiated by such foundational patents has directly contributed to the development of a significant class of modern therapeutics.
What is the expiration date of U.S. Patent 5,863,935 and what are its implications?
U.S. Patent 5,863,935 was granted on January 26, 1999. Under U.S. patent law at the time of its filing, utility patents generally have a term of 20 years from the date on which the application for the patent was filed.
Assuming a typical priority date calculation, the patent's term likely began from the filing date of the earliest-filed application to which it claims priority. For a patent granted in 1999, this typically means the application was filed in the mid-to-late 1990s.
Therefore, U.S. Patent 5,863,935 has expired. Its term would have concluded approximately 20 years after its filing date. For a patent granted in 1999, the filing date was likely around 1997 or 1998, meaning the patent expired between 2017 and 2018.
Implications of expiration:
- Loss of Exclusivity: The expiration of this patent means that the broad claims covering the general formula of pyrrolo[2,3-d]pyrimidine compounds, pharmaceutical compositions containing them, and their general use for treating kinase-mediated diseases are no longer exclusively held by the patent holder (or its successors, such as GSK plc).
- Opportunities for Generics and Biosimilars (where applicable to compounds): While this patent covers small molecules, expired patents allow generic manufacturers to produce and market identical or structurally equivalent compounds, provided no other valid patents (e.g., covering specific polymorphs, formulations, or new indications) are in force.
- Freedom to Operate for New Research: Researchers and companies can now conduct R&D and develop new products based on the chemical structures and general therapeutic uses defined by this expired patent without infringing on this specific patent. This can spur further innovation and development of next-generation therapies.
- Focus Shifts to Later-Stage Patents: The competitive landscape for drugs based on the pyrrolo[2,3-d]pyrimidine scaffold now relies on the patent protection of more specific compounds, formulations, manufacturing processes, and method-of-use patents that may have been filed subsequently by various entities. For instance, specific drugs like tofacitinib, ruxolitinib, and baricitinib are protected by their own later-expiring patents.
The expiration of foundational patents like 5,863,935 is a natural part of the pharmaceutical innovation lifecycle, opening doors for wider accessibility and further research.
What is the relationship between U.S. Patent 5,863,935 and later patents on specific JAK inhibitors?
U.S. Patent 5,863,935 serves as an early, foundational patent that broadly protected the pyrrolo[2,3-d]pyrimidine scaffold and its potential as a class of kinase inhibitors. Later patents on specific JAK inhibitors, such as those related to tofacitinib, ruxolitinib, and baricitinib, have a crucial relationship with this earlier patent:
- Broad vs. Specific Claims: U.S. Patent 5,863,935 claims a broad genus of compounds defined by a general chemical structure. Later patents typically claim specific chemical entities (species) within this genus, or closely related analogs, that have been identified as having desirable pharmacological properties (e.g., higher potency, greater selectivity for specific JAK isoforms, better pharmacokinetic profiles, reduced toxicity).
- Enablement and Disclosure: The earlier patent, like 5,863,935, provides the fundamental disclosure and enablement for the pyrrolo[2,3-d]pyrimidine scaffold. This early disclosure is often a prerequisite for later patents. Without the initial disclosure of the scaffold, subsequent patents claiming specific compounds derived from it might face challenges.
- Patent Term Extension and Supplementary Protection: While U.S. Patent 5,863,935 has expired, the later patents covering specific, marketed JAK inhibitors often have longer effective terms due to mechanisms like Patent Term Extension (PTE) in the U.S. and Supplementary Protection Certificates (SPCs) in Europe, which compensate for regulatory review delays. This allows for extended market exclusivity for the specific approved drugs.
- Navigating Prior Art: Later patent applications must demonstrate novelty and inventiveness over existing prior art, which includes earlier patents like 5,863,935. If a specific compound or its use was adequately disclosed in the earlier patent, it could invalidate a later patent. Therefore, developers of new JAK inhibitors had to carefully design their compounds and applications to fall outside the scope of the claims of 5,863,935 and other relevant prior art.
- Licensing and Freedom to Operate: For companies developing compounds that fall within the broad scope of an expired foundational patent like 5,863,935, they gained "freedom to operate" regarding those broad claims. However, they still need to ensure they do not infringe on any later, still-active patents covering specific compounds, formulations, or methods of use that are currently marketed. Conversely, if a company wished to develop a compound that was specifically claimed in 5,863,935, they would have had to secure a license from SmithKline Beecham Corporation during its active term.
In essence, U.S. Patent 5,863,935 laid the groundwork by identifying the pyrrolo[2,3-d]pyrimidine scaffold as a promising area for drug discovery. Subsequent patent filings have built upon this foundation by identifying and protecting specific, optimized molecules and their refined therapeutic applications, which are now the basis of marketed JAK inhibitor therapies.
What are the implications for ongoing R&D and investment in the JAK inhibitor space?
The expiration of U.S. Patent 5,863,935 and the landscape of subsequent patents have significant implications for ongoing research and investment in the JAK inhibitor space:
- Shift to Next-Generation Selectivity and Efficacy: With the foundational patent expired and leading JAK inhibitors (like tofacitinib, ruxolitinib, baricitinib) well-established and protected by their own later patents, R&D efforts are increasingly focused on developing next-generation inhibitors. This includes compounds with even greater selectivity for specific JAK isoforms (e.g., JAK1-selective inhibitors for inflammatory diseases, JAK2-selective for myeloproliferative neoplasms) or dual JAK/other kinase inhibition. The goal is to achieve improved efficacy and further reduce off-target side effects.
- Broader Therapeutic Indications: Investment is also directed towards exploring new therapeutic areas for JAK inhibition. Beyond traditional autoimmune and inflammatory diseases, research is active in fibrotic diseases, neurological disorders, infectious diseases, and various cancers. Identifying novel indications for existing or new JAK inhibitors will be a key driver for future patent filings and market opportunities.
- Combination Therapies: The development of combination therapies, where JAK inhibitors are used with other agents (e.g., immunomodulators, targeted therapies, chemotherapy), is a significant R&D area. Patents in this space often cover the combination itself, specific dosing regimens, or synergistic effects.
- Formulation and Delivery Innovation: Investment continues in improving drug delivery and patient convenience. This includes developing extended-release formulations, topical JAK inhibitors for skin conditions, and potentially novel administration routes. Patents in this area are critical for extending product life cycles and differentiating offerings.
- Biosimilar/Generic Landscape for Specific Drugs: While 5,863,935 is expired, the specific blockbuster JAK inhibitors remain protected by their own patents. As these later patents approach expiration, the market will open to generic competition, impacting pricing and market share for those specific drugs. This drives investment in developing cost-effective manufacturing processes for generics.
- Diversification of Kinase Targets: The success of JAK inhibitors has spurred investment in the broader field of kinase inhibition. Companies are exploring other kinase families and signaling pathways, using the insights gained from JAK inhibitor development to inform their strategies.
- Valuation and Investment Strategy: For investors, understanding the patent expiry timelines for key JAK inhibitors and the scope of existing and emerging patents is critical. Investment decisions will focus on companies with robust pipelines of differentiated next-generation inhibitors, novel therapeutic indications, or innovative formulation technologies that can secure new market exclusivity. The expiration of foundational patents like 5,863,935 signals a mature market for the broad class but highlights opportunities in specific niches and advanced developments.
The JAK inhibitor space remains a dynamic area for R&D and investment, driven by the ongoing need for more effective and targeted treatments for a wide range of diseases.
Key Takeaways
U.S. Patent 5,863,935, granted in 1999, broadly protected a class of pyrrolo[2,3-d]pyrimidine compounds and their use in treating kinase-mediated diseases. The patent has expired, removing its exclusivity. This foundational patent enabled subsequent development of specific, highly successful JAK inhibitors like tofacitinib, ruxolitinib, and baricitinib, which are protected by their own later-expiring patents. The ongoing R&D and investment in this field are focused on next-generation selective inhibitors, new therapeutic indications, innovative formulations, and combination therapies, driven by the need for improved patient outcomes and sustained market exclusivity.
Frequently Asked Questions
-
Does the expiration of U.S. Patent 5,863,935 allow any company to market Tofacitinib or Ruxolitinib?
No. While U.S. Patent 5,863,935 has expired, specific marketed drugs like Tofacitinib and Ruxolitinib are protected by their own separate, later-expiring patents that cover their precise chemical structures, formulations, and approved uses. Generic or biosimilar entry for these specific drugs is contingent on the expiration of those later patents.
-
What is the primary mechanism of action for the compounds claimed in U.S. Patent 5,863,935?
The compounds are claimed to inhibit kinase activity, particularly Janus kinases (JAKs), which are critical mediators of inflammatory and immune signaling pathways.
-
Can I develop a new drug based on the pyrrolo[2,3-d]pyrimidine scaffold now that U.S. Patent 5,863,935 has expired?
You can develop new compounds based on the pyrrolo[2,3-d]pyrimidine scaffold and pursue their patent protection. However, you must ensure that your specific new compounds, their synthesis, formulations, and intended uses do not infringe on any currently active patents held by other entities, particularly those covering specific marketed JAK inhibitors or novel applications.
-
What are the main types of diseases that U.S. Patent 5,863,935 claimed to treat?
The patent claimed treatment for inflammatory diseases, autoimmune diseases, allergic conditions, certain cancers (including myeloproliferative disorders), and organ transplant rejection, all predicated on being mediated by kinase activity.
-
If I were to conduct research on pyrrolo[2,3-d]pyrimidine compounds today, what would be the key patent considerations?
Key considerations would include performing thorough prior art searches to understand the existing patent landscape, identifying novel chemical structures or improved therapeutic uses not already claimed, focusing on developing compounds with superior selectivity, efficacy, or safety profiles, and securing patent protection for these new innovations. Additionally, understanding the expiry dates of patents for existing marketed drugs in this class is crucial for freedom-to-operate analysis.
Citations
[1] SmithKline Beecham Corporation. (1999). U.S. Patent 5,863,935. United States Patent and Trademark Office. Retrieved from [USPTO Patent Database - search for 5,863,935] (Actual retrieval link not possible without live database access).
More… ↓
⤷ Start Trial
|
